Total value of deals worth more than €5 billion rose by 150% to €533 billion, while the number of such deals grew 10%, according to Mergermarket Deal Drivers EMEA 2015 Full-Year Edition.
Against a backdrop of subdued global economic activity, including volatility in the Chinese market, falling energy and other commodity prices, and weak manufacturing activity, European financing conditions have remained favorable and supportive of a buoyant M&A market. This is due to a combination of corporates seeking growth, positive economic indicators and cheap debt, according to Mergermarket Deal Drivers EMEA 2015 Full-Year Edition, produced with Merrill Corporation. That said, deal value in 2015 increased by 47% to €1 trillion—the greatest deal value seen since 2007, before the financial crisis. Of the top 20 deals in EMEA, four took place in the pharma, medical and biotech sector, with the largest deal on record involving US-based Pfizer’s acquisition of Ireland-based Allergan for €172.6 billion. Find out what other sectors exhibited strong M&A activity across Europe, the Middle East and North Africa. Track dealmaking as well as key trends across specific countries.
- EMEA heat chart tracking “companies for sale” stories by sector and country
- Top 20 announced deals for 2015 across all sectors
- Top 15 deal breakdowns by value, sector, type, geographic region—plus top 20 financial, legal and PR advisor rankings